KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLoans and Notes ReceivablesLong-Term Debt IssuancesNon-Current ReceivablesReceivables RefundsShares OutstandingShares Repurchased
Ratios

Royalty Pharma (RPRX) Long-Term Debt Issuances (2020 - 2025)

Historic Long-Term Debt Issuances for Royalty Pharma (RPRX) over the last 4 years, with Q3 2025 value amounting to $2.0 billion.

  • Royalty Pharma's Long-Term Debt Issuances changed N/A to $2.0 billion in Q3 2025 from the same period last year, while for Dec 2025 it was $2.0 billion, marking a year-over-year increase of 45842.14%. This contributed to the annual value of $2.0 billion for FY2025, which is 3284.59% up from last year.
  • Per Royalty Pharma's latest filing, its Long-Term Debt Issuances stood at $2.0 billion for Q3 2025.
  • Over the past 5 years, Royalty Pharma's Long-Term Debt Issuances peaked at $2.0 billion during Q3 2025, and registered a low of $350.0 million during Q4 2023.
  • Moreover, its 3-year median value for Long-Term Debt Issuances was $1.3 billion (2021), whereas its average is $1.2 billion.
  • Within the past 5 years, the most significant YoY rise in Royalty Pharma's Long-Term Debt Issuances was 7825.11% (2021), while the steepest drop was 7825.11% (2021).
  • Royalty Pharma's Long-Term Debt Issuances (Quarter) stood at $1.3 billion in 2021, then plummeted by 72.5% to $350.0 million in 2023, then soared by 458.42% to $2.0 billion in 2025.
  • Its Long-Term Debt Issuances stands at $2.0 billion for Q3 2025, versus $350.0 million for Q4 2023 and $1.3 billion for Q3 2021.